ESC 365 - Prospects for clinical benefit with CETP inhibition in light of current and future trials.

Open Access

Prospects for clinical benefit with CETP inhibition in light of current and future trials.

Session: Cardiovascular risk reduction and lipid management: state of the science

Topic: Metabolism and metabolic syndromes

Speaker: Professor A. Lincoff (Cleveland, US)

Sponsored by Cleveland Clinic

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor A Michael Lincoff

Cleveland Clinic Hospital, Cleveland (United States of America)

6 presentations

0 follower

3 more presentations in this session

Unmet medical needs with current agents and residual CV risk: rationale for developing new agents.

Speaker: Professor S. Nissen (Cleveland, US)

New horizons for the statin intolerant patients: current and future therapeutic options.

Speaker: Doctor L. Cho (Cleveland, US)

The science of HDL and reverse cholesterol transport – Are we still hopeful?

Speaker: Professor J. Kastelein (Amsterdam, NL)

Access the full session

Cardiovascular risk reduction and lipid management: state of the science

Speakers: Professor A. Lincoff, Professor S. Nissen, Doctor L. Cho, Professor J. Kastelein

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources